
NBA sued by investors over ties to failed crypto exchange Voyager
Group of investors allege the NBA's negligence led to losses of more than $4.2 billion.
Watch CBS News
Kate Gibson is a Reporter for CBS MoneyWatch in New York, where she covers business and consumer finance. She previously worked for CNBC and MarketWatch and has written for national news outlets, including Barron's, the Wall Street Journal and the Chicago Tribune.
Group of investors allege the NBA's negligence led to losses of more than $4.2 billion.
FBI recently toppled international criminal enterprise that targeted 1,500 institutions in more than 80 countries.
There have been almost two dozen reports of burns related to the handheld devices spewing hot water while heating or in use.
Ruling takes effect immediately and gives state attorneys general a new tool to go after bad actors behind nefarious calls.
Here's a rundown of tickets and average prices, from the cheapest to the most expensive.
Snoop Dogg and Master P say Walmart hid their products in stockrooms and Post set its price at an unaffordable $10 a box.
Disease investigators have identified the source of a decade-old listeria outbreak that killed two people and sickened others in 11 states.
The plane manufacturer's employees are being encouraged to use a FAA hotline to report any safety concerns, the agency's leader says.
Honda is recalling a range of models because the front-seat passenger air bags may deploy unintentionally.
Having advanced driver-assistance systems doesn't mean motorists get to zone out, Transportation Secretary says.
4chan users vied to get around filters designed to block pornography by image-generation services, study finds.
Spotify, the world's biggest audio streaming service, is signing a new multiyear deal with podcast host Joe Rogan.
The first jobs report of 2024 shows the U.S. economy remains resilient despite the Federal Reserve jacking up interest rates.
The move by the 39-year-old to one of the most iconic teams in the history of motorsports marks the end of a remarkably successful partnership.
Update from the Food and Drug Agency comes days after Philips said it would stop selling the devices in the U.S.